Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
NCT03289143 · Genentech, Inc. · PHASE2 · terminated · last registry update 2022-03-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.” | – | Registry record, Genentech, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-11-08Results posted on the registry: Biogen, BIIB092 + Placebo (NCT03352557)
- 2022-11-08Also stopped (terminated): Biogen, BIIB092 + Placebo (NCT03352557)
- 2022-10-03Results posted on the registry: Genentech, Inc., Semorinemab + Placebo (NCT03828747)
- 2022-09-22Results posted on the registry: AbbVie, Tilavonemab (NCT03712787)
- 2022-09-22Also stopped (terminated): AbbVie, Tilavonemab (NCT03712787)
- 2022-08-30Results posted on the registry: Eli Lilly and Company, Zagotenemab + Placebo (NCT03518073)
- 2022-08-26Results posted on the registry: AbbVie, ABBV-8E12 + placebo for ABBV-8E12 (NCT02880956)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision